Natalizumab increases your risk of getting a rare but very serious (sometimes fatal) brain infection (progressive multifocal leukoencephalopathy-PML). This risk may be higher the longer you use natalizumab and if you are also using other medications that weaken the immune system, such as other multiple sclerosis (MS) treatments (such as interferon) or immunosuppressants (such as azathioprine). (See also Side Effects...
Read moreAn article in the August 1 edition of The Wall Street Journal reports that two patients treated with Tysabri have contracted progressive... Read more »
Tysabri has been in the news again this week. Last Friday the European Medicines Agency (EMEA) announced that they would review the... Read more »
Tysabri, a drug initially used to treat Multiple Sclerosis has been approved for use in certain patients with Crohn's disease. This drug is... Read more »
Our thoughts are with the patients and families in Europe who recently developed PML (Progressive Multifocal Leukoencephalopathy) on... Read more »
Of the available disease-modifying treatments for multiple sclerosis, Tysabri (natalizumab) has arguably been the most controversial to... Read more »
The U.S. Food and Drug Administration has updated the safety information for the drug Tysabri to take into account the incidence of a rare brain... Read more »
The U.S. Food and Drug Administration has placed a new warning label on the multiple sclerosis (MS) drug Tysabri, one that warns doctors and patients... Read more »
According to a new study, Tysabri significantly increases the proportion of disease-free patients with relapsing multiple sclerosis (MS) compared... Read more »
New research suggests that the drug Tysabri may regenerate and stabilize damage done to the myelin sheath in people with multiple sclerosis (MS). In... Read more »
Researchers are reporting that a potential treatment for a sometimes fatal side effect of the multiple sclerosis (MS) drug Tysabri is currently under... Read more »